Stockscreener 앱 받기
202.31
1.46%
-2.95
전일 마감가:
$205.26
열려 있는:
$206.85
하루 거래량:
451.36K
Relative Volume:
0.18
시가총액:
$43.37B
수익:
$742.00K
순이익/손실:
$-1.37B
주가수익비율:
-28.60
EPS:
-7.0731
순현금흐름:
$-1.07B
1주 성능:
+2.25%
1개월 성능:
+9.95%
6개월 성능:
+110.01%
1년 성능:
+460.74%
1일 변동 폭
$202.31
$206.85
1주일 범위
$196.49
$208.76
52주 변동 폭
$35.22
$208.76
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
202.34 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
517.83 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.25 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
863.31 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
356.10 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake - Stock Titan
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript - AOL.com
(RVMD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revolution and BeOne Meds enter research pact - The Pharma Letter
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest. - Pluang
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - finance.yahoo.com
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value - simplywall.st
Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand - finance.yahoo.com
Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) DealHas The Bull Case Changed? - finance.yahoo.com
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach - finance.yahoo.com
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach? - finance.yahoo.com
BeOne and Revolution Medicines partner for oncology therapies - Pharmaceutical Business review -
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies - Pharmaceutical Executive
REVOLUTION MEDICINES, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $231 FROM $210 - Bitget
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighShould You Buy? - MarketBeat
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus - simplywall.st
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia - AllSci
Revolution Medicines stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies - Oncodaily
Revolution Medicines, BeOne Medicines form collaboration on RAS cancer drug combinations - Bitget
BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration - TradingView
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration - Business Wire
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Powerhouse with a Bold Vision for Cancer Treatment - DirectorsTalk Interviews
REVOLUTION MEDICINES, INC. : JP MORGAN RAISES TARGET PRICE TO $227 FROM $205 - Bitget
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next - webull.com
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD - MarketBeat
LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $291 - moomoo.com
Sei Investments Co. Cuts Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years - Sahm
'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug - The Business Journals
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $201 to $240 - Moomoo
High Risk, High Reward: Inside The Revolution Medicines Bull Case (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines nears commercial launch wi... - Pluang
Oppenheimer Adjusts PT on Revolution Medicines to $230 From $195, Maintains Outperform Rating - Moomoo
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View - tradingview.com
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $216.4, Implies 10% Upside - TradingView
RBC Adjusts PT on Revolution Medicines to $203 From $182, Maintains Outperform Speculative Risk Rating - marketscreener.com
Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00 - MarketBeat
Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highligh - GuruFocus
Revolution Medicines Q2 Earnings Call Highlights - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results - MarketBeat
Revolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses - Endpoints News
Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026 - Investing.com
Revolution Medicines, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Revolution Medicines falls on second quarter earnings miss By Investing.com - Investing.com Nigeria
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings - 24/7 Wall St.
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Revolution Medicines Inc 주식 (RVMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Director |
Jun 29 '26 |
Sale |
187.99 |
5,580 |
1,048,967 |
21,656 |
0.96%
1.12%
자본화:
|
볼륨(24시간):